The epigenetic reprogramming of the drug tolerant cells may be distinct depending on the tumor type or the therapeutic interventions, as KDM4A, which we show is increased upon TKI treatment in TNBC cell line in Figure 3, is not significantly regulated in other cancers analyzed in Figure 5. This evidence concerns the gene KDM4A and neoplasm.